NovoCure PANOVA-3 pancreatic cancer trial passes interim DMC review; continues to final analysis

NovoCure Ltd

Independent DMC recommended continuation of phase 3 PANOVA-3 trial for unresectable, locally advanced pancreatic cancer.
Trial evaluating TTFields plus nab-paclitaxel/gemcitabine is fully enrolled; final data expected in 2024.
No efficacy or safety data disclosed; trial proceeds as planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.